Carmofur

A pyrimidine analogue.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Carmofur is an antineoplastic drug derived from 5-fluorouracil (NCIt).

Carmofur on DrugBank
Carmofur on PubChem
Carmofur on Wikipedia

Link	Tested on	Impact factor	Notes	Publication date
Discovering drugs to treat coronavirus disease 2019 (COVID-19).	in silico			Feb/22/2020
Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2 Small molecule Enzyme assay Screening	in vitro	6.71	Inhibits SARS-CoV-2 3C-like protease in vitro.	Jul/28/2020

Link	Publication date
Discovery of a "Cocktail" of Potential SARS-COV-2 Main Protease Inhibitors through Virtual Screening of Known Chemical Components of Vitex negundo L. ("Lagundi").	Jun/22/2021
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.	Oct/04/2020
Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.	Oct/09/2020
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor	May/12/2022
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays	May/05/2021
Structural modification of antineoplastic drug carmofur designed to the inhibition of SARS-CoV-2 main protease: A theoretical investigation	Dec/09/2021
Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate molecules	Apr/19/2022
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition	Jan/28/2022